Ambit Biosciences Private

Ambit Biosciences is a privately-held biopharmaceutical company engaged in the discovery and development of small molecule kinase inhibitors for the treatment of cancer, inflammatory disease, and other indications. Ambit's lead compound, AC220, is a novel, potent, highly selective, orally bioavailable FMS-like tyrosine kinase-3 (FLT3) inhibitor, and is currently under clinical investigation in patients with relapsed or refractory AML. Ambit is developing AC220 in collaboration with Astellas Pharma Inc. as part of a worldwide agreement to jointly develop and commercialize FLT3 kinase inhibitors in oncology and non-oncology indications. In addition to AC220, Ambit's clinical pipeline includes AC480, a pan-HER inhibitor, and AC430, an oral JAK2 inhibitor. Ambit also has a pipeline of preclinical candidates which includes CEP-32496, a BRAF inhibitor licensed to Cephalon.

Investors

Technology: Immunotherapy
Headquarters: San Diego, California, United States
Funding Status: M&A
Founded Date: 2000
Last Funding Type: Venture - Series Unknown
Investors Number: 15
Last Funding Date: 2012-11-06
Estimated Revenue: $10M to $50M
Employee Number: 51-100
Total Funding: 215727869 USD
Industry: PharmTech
Register and Claim Ownership